Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma's stock has experienced significant volatility and a general decline over the past six months. In April 2025, the stock plummeted to a 52-week low. Shareholder approved the issuance of new shares of common stock. There were resignations of board members. Investment firm 111 Equity Group increased its stake in the company to 5.17%. In November 2025, the company announced that CFO Keith Kucinski would step down in January 2026, with CEO Jerome Jabbour being appointed interim CFO in January 2026. The stock price gained 7.73% on February 6, 2026, but was still down by -14.42% for the preceding 10-day period. The stock has traded between a high of $3.09 and a low of $0.47 over the past 52 weeks.

The demand for Matinas BioPharma's products is primarily driven by medical need, clinical trial progress, and regulatory approvals. There is no readily available information to suggest significant demand seasonality for Matinas BioPharma's products or services.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel pharmaceutical products using its Lipid Nanocrystal (LNC) platform delivery technology. Its major product candidates include MAT2203, an oral formulation of amphotericin B, and MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with entities like the National Institute of Allergy and Infectious Diseases, BioNTech SE, and Genentech Inc.

Matinas BioPharma Holdings, Inc. is based in Bedminster, New Jersey, where it commenced operations in 2013.

In the past year, Matinas BioPharma's financial health was rated as 'WEAK' by InvestingPro in April 2025, which could negatively impact its brand reputation. The significant drop in stock price to a 52-week low also reflects challenges the company has faced in the market. News of board member resignations could also be perceived negatively. However, the increased stake by 111 Equity Group suggests some investor confidence in the company's future.

Matinas BioPharma Holdings, Inc. has 35 institutional owners and shareholders holding a total of 330,108 shares. Approximately 1.83% of the company's stock is owned by institutional investors, while insiders own 13.11%. Jerome D. Jabbour, the Co-founder, Chairman, and Chief Executive Officer, owns the most shares among individuals. Major institutional owners include Vanguard Group Inc, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, BlackRock, Inc., Sargent Investment Group, LLC, Holos Integrated Wealth LLC, Renaissance Technologies Llc, Northern Trust Corp, State Street Corp, and Two Sigma Securities, Llc.